Biotech Investor

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

Amylin agonists are the next wave of #obesity drugs following the GLP-1s because they are likely to spare muscle Competition is intense with several mid-stage compounds: $LLY $NVO $ABBV $MTSR #ZEAL $ANZ Who will win? #learnbiotechinvesting #biotech #investing #BiotechPrometheus

Pharma needs to replace significant revenue from expiring patents over the next 6 years By some measures, $MRK $GSK $AMGN will be most impacted $JNJ $RHHBY $ABBV may be least impacted #Biotech offers a way to replace revenue Companies that can fill these revenue gaps will be considered likely takeout targets #learnbiotechinvesting #biotech #investing #BiotechPrometheus

Amylin agonists are the next wave of #obesity drugs following the GLP-1s b/c they are likely to spare muscle Competition is intense with several mid-stage compounds: $LLY $NVO $ABBV $MTSR #ZEAL $ANZ Who will win? #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/E6Y6iVTNtq

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #BiotechPrometheus https://t.co/ahOr7SGSMb

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #BiotechPrometheus https://t.co/c4jSYzrf35